Pharming Group promoted to the Euronext AMX® index
Corporate updatesPharming Group N.V. today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.
Pharming Group N.V. today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.
Pharming Group N.V. today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025.
For media and investors only
Pharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
Pharming Group N.V. announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST.
For media and investors only
Pharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Pharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET.
Pharming Group N.V. announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming’s new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.
Pharming Group N.V. announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.